A systematic review of p53 as a prognostic factor of survival in squamous cell carcinoma of the four main anatomical subsites of the head and neck

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 2, 2010, Pages 574-587

  Tandon, Sankalap ^a,b   Tudur Smith, Catrin ^b   Riley, Richard D ^c   Boyd, Mark T ^b   Jones, Terence M ^a,b  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

DISEASE FREE SURVIVAL; HAZARD RATIO; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; MOUTH CARCINOMA; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW;

CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; HEAD AND NECK NEOPLASMS; HUMANS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 76149140884     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0981     Document Type: Review

References (77)

1. Soussi T. p53 alterations in human cancer: more questions than answers. Oncogene 2007;26:2145-56.
2. Vousden KH. Outcomes of p53 activation-spoilt for choice. J Cell Sci 2006;119:5015-20.
3. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007;28:622-9.
4. Lu ML, Wikman F, Orntoft TF, et al. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res 2002;8: 171-9.
5. In: Wilson JA, editor. Effective head and neck cancer management. Third consensus document. London: British Association of Otorhinolaryngologists Head and Neck Surgeons; 2002.
6. Rafferty MA, Fenton JE, Jones AS. The history, aetiology and epidemiology of laryngeal carcinoma. Clin Otolaryngol Allied Sci 2001;26: 442-6.
7. zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology 2009;384:260-5.
8. Nenutil R, Smardova J, Pavlova S, et al. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 2005;207:251-9.
9. Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 2005;97:1043-55.
10. Timar J, Csuka O, Remenar E, Repassy G, Kasler M. Progression of head and neck squamous cell cancer. Cancer Metastasis Rev 2005; 24:107-27.
11. Altman DG, Riley RD. Primer: an evidence-based approach to prognostic markers. Nat Clin Pract Oncol 2005;2:466-72.
12. Riley RD, Abrams KR, Sutton AJ, et al. Reporting of prognostic markers: current problems and development of guidelines for evidencebased practice in the future. Br J Cancer 2003;88:1191-8.
13. Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Stat Med 2002;21: 3337-51.
14. Taylor RJ. "Mouseyes": an aid to wound measurement using a computer. J Wound Care 1997;6:123-6.
15. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
16. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc 2009;172: 137-59.
17. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002;21:1539-58.
18. Deeks JJ, Higgins JPT, Altman DG. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, Engand: John Wiley & Sons Ltd.; 2008, p. 243-36.
19. Sterne JAC, Egger M, Moher D. Addressing reporting biases. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, Engand: John Wiley & Sons Ltd.; 2008, p. 297-334.
20. Awwad S, Jaros E, Somes J, Lunec J. P53 overexpression in head and neck carcinoma and radiotherapy results. Int J Radiat Oncol Biol Phys 1996;34:323-32.
21. Buyukbayram H, Cureoglu S, Arslan A, Isikakdogan AR. Prognostic value of PCNA and mutant p53 expression in laryngeal squamous cell carcinoma. Cancer Invest 2004;22:195-202.
22. Caminero MJ, Nunez F, Suarez C, Ablanedo P, Riera JR, Dominguez F. Detection of p53 protein in oropharyngeal carcinoma. Prognostic implications. Arch Otolaryngol Head Neck Surg 1996;122:769-72.
23. Chien CY, Huang CC, Cheng JT, Chen CM, Hwang CF, Su CY. The clinicopathological significance of p53 and p21 expression in squamous cell carcinoma of hypopharyngeal cancer. Cancer Lett 2003; 201:217-23.
24. Cho JH, Kim HS, Park CS, et al. Maspin expression in early oral tongue cancer and its relation to expression of mutant-type p53 and vascular endothelial growth factor (VEGF). Oral Oncol 2007;43: 272-7.
25. Chomchai JS, Du W, Sarkar FH, et al. Prognostic significance of p53 gene mutations in laryngeal cancer. Laryngoscope 1999;109:455-9.
26. Costa A, Licitra L, Veneroni S, et al. Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancers. Int J Cancer 1998;79:619-23.
27. de Aguiar AF, Jr., Kowalski LP, de Almeida OP. Clinicopathological and immunohistochemical evaluation of oral squamous cell carcinoma in patients with early local recurrence. Oral Oncol 2007;43:593-601.
28. Fan GK, Fujieda S, Sunaga H, Tsuzuki H, Ito N, Saito H. Expression of protein p27 is associated with progression and prognosis in laryngeal cancer. Laryngoscope 1999;109:815-20.
29. Frank JL, Bur ME, Garb JL, et al. p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx. Cancer 1994;73:181-6.
30. Friedman M, Lim JW, Manders E, et al. Prognostic significance of Bcl-2 and p53 expression in advanced laryngeal squamous cell carcinoma. Head Neck 2001;23:280-5.
31. Friesland S, Mellin H, Munck-Wikland E, et al. Human papilloma virus (HPV) and p53 immunostaining in advanced tonsillar carcinoma-relation to radiotherapy response and survival. Anticancer Res 2001; 21:529-34.
32. Grabenbauer GG, Muhlfriedel C, Rodel F, et al. Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify patients at high risk for local recurrence after surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 2000;48:1041-50.
33. Hiranuma H, Jikko A, Maeda T, et al. An analysis of the prognostic significance of p53 status for squamous cell carcinoma of the oral cavity treated by radiotherapy. Oral Oncol 1998;34:513-8.
34. Hirvikoski P, Kumpulainen E, Virtaniemi J, et al. p53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carcinoma. J Clin Oncol 1997;15:3111-20.
35. Homma A, Furuta Y, Oridate N, et al. Correlation of clinicopathological parameters and biological markers related to apoptosis and proliferative activity with a clinical outcome in squamous cell carcinoma of the larynx treated with concurrent chemoradiotherapy. Auris Nasus Larynx 2001;28 Suppl:S87-94.
36. Jackel MC, Sellmann L, Dorudian MA, Youssef S, Fuzesi L. Prognostic significance of p53/bcl-2 co-expression in patients with laryngeal squamous cell carcinoma. Laryngoscope 2000;110:1339-45.
37. Jayasurya R, Sathyan KM, Lakshminarayanan K, et al. Phenotypic alterations in Rb pathway have more prognostic influence than p53 pathway proteins in oral carcinoma. Mod Pathol 2005;18:1056-66.
38. Jeannon JP, Soames J, Lunec J, Awwad S, Ashton V, Wilson JA. Expression of cyclin-dependent kinase inhibitor p21(WAF1) and p53 tumour suppressor gene in laryngeal cancer. Clin Otolaryngol Allied Sci 2000;25:23-7.
39. Kozomara R, Jovic N, Magic Z, Brankovic-Magic M, Minic V. p53 mutations and human papillomavirus infection in oral squamous cell carcinomas: correlation with overall survival. J Craniomaxillofac Surg 2005;33:342-8.
40. Miyahara H, Yane K, Naitoh H, et al. p53 tumor suppressor gene and ras oncogene mutations in hypopharyngeal squamous cell carcinomas. Int J Oncol 1997;11:133-7.
41. Nadal A, Campo E, Pinto J, et al. p53 expression in normal, dysplastic, and neoplastic laryngeal epithelium. Absence of a correlation with prognostic factors. J Pathol 1995;175:181-8.
42. Nakashima T, Wang XF, Masuda M, Inokuchi A, Komiyama S. Over-expression of p53 nuclear protein in premalignant and malignant laryngeal lesions. Eur Arch Otorhinolaryngol 1999;256 Suppl 1:S56-9.
43. Narayana A, Vaughan AT, Kathuria S, Fisher SG, Walter SA, Reddy SP. P53 overexpression is associated with bulky tumor and poor local control in T1 glottic cancer. Int J Radiat Oncol Biol Phys 2000;46: 21-6.
44. Nibu KI, Yanagisawa A, Nakamizo M, et al. Clinical role of p53 and p21WAF1/CIP1 in squamous cell carcinoma of the pyriform sinus. Acta Otolaryngol 1998;118:432-7.
45. Obata A, Eura M, Sasaki J, et al. Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx. Int J Cancer 2000;89:187-93.
46. Otero-Garcia JE, Youssef E, Enamorado II, et al. Prognostic significance of p53 and FHIT in advanced oropharyngeal carcinoma. Am J Otolaryngol 2004;25:231-9.
47. Pai HH, Rochon L, Clark B, Black M, Shenouda G. Overexpression of p53 protein does not predict local-regional control or survival in patients with early-stage squamous cell carcinoma of the glottic larynx treated with radiotherapy. Int J Radiat Oncol Biol Phys 1998;41:37-42.
48. Parikh RR, Yang Q, Haffty BG. Prognostic significance of vascular endothelial growth factor protein levels in T1-2 N0 laryngeal cancer treated with primary radiation therapy. Cancer 2007;109:566-73.
49. Pruneri G, Pignataro L, Manzotti M, et al. p63 in laryngeal squamous cell carcinoma: evidence for a role of TA-p63 down-regulation in tumorigenesis and lack of prognostic implications of p63 immunoreactivity. Lab Invest 2002;82:1327-34.
50. Pulkkinen JO, Klemi P, Martikainen P, Grenman R. Apoptosis in situ, p53, bcl-2 and AgNOR counts as prognostic factors in laryngeal carcinoma. Anticancer Res 1999;19:703-7.
51. Rowley H, Roland NJ, Helliwell TR, Caslin A, Kinsella AR, Jones AS. p53 protein expression in tumours from head and neck subsites, larynx and hypopharynx, and differences in relationship to survival. Clin Otolaryngol Allied Sci 1998;23:57-62.
52. Russo A, Corsale S, Agnese V, et al. TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma. J Cell Physiol 2006;206:181-8.
53. Shigyo H, Nonaka S, Katada A, et al. Inducible nitric oxide synthase expression in various laryngeal lesions in relation to carcinogenesis, angiogenesis, and patients' prognosis. Acta Otolaryngol 2007;127: 970-9.
54. Siegelmann-Danieli N, Ben-Izhack O, Hanlon A, et al. P53 alteration in oral tongue cancer is not significantly associated with age at diagnosis or tobacco exposure. Tumori 2005;91:346-50.
55. Sittel C, Eckel HE, Damm M, von Pritzbuer E, Kvasnicka HM. Ki-67 (MIB1), p53, and Lewis-X (LeuM1) as prognostic factors of recurrence in T1 and T2 laryngeal carcinoma. Laryngoscope 2000;110:1012-7.
56. Tan LK, Ogden GR. p53 over-expression in laryngeal carcinoma is not predictive of response to radiotherapy. Oral Oncol 1997;33: 177-81.
57. Tatemoto Y, Osaki T, Yoneda K, Yamamoto T, Ueta E, Kimura T. Expression of p53 and p21 proteins in oral squamous cell carcinoma: correlation with lymph node metastasis and response to chemoradiotherapy. Pathol Res Pract 1998;194:821-30.
58. Tsuji T, Mimura Y, Wen S, et al. The significance of PCNA and p53 protein in some oral tumors. Int J Oral Maxillofac Surg 1995;24: 221-5.
59. Vielba R, Bilbao J, Ispizua A, et al. p53 and cyclin D1 as prognostic factors in squamous cell carcinoma of the larynx. Laryngoscope 2003;113:167-72.
60. Yanamoto S, Kawasaki G, Yoshitomi I, Mizuno A. p53, mdm2, and p21 expression in oral squamous cell carcinomas: relationship with clinicopathologic factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;94:593-600.
61. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007;357:2552-61.
62. Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 2002;21:1510-7.
63. Hafkamp HC, Speel EJ, Haesevoets A, et al. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer 2003;107:394-400.
64. Hubbert NL, Sedman SA, Schiller JT. Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes. J Virol 1992;66:6237-41.
65. Hafkamp HC, Manni JJ, Haesevoets A, et al. Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer 2008;122:2656-64.
66. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100: 261-9.
67. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008;26:3128-37.
68. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 2005;114: 806-16.
69. Tandon S, Beer H, Jones TM, Birchall M, Boyd M, Helliwell TR. Immunohistochemical expression of p53 and MDM2 within head and neck squamous cell carcinoma. Clin Otolaryngol Allied Sci 2006; 31:247.
70. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 2007;43:2559-79.
71. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4.
72. Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006; 144:427-37.
73. Malats N, Bustos A, Nascimento CM, et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005;6:678-86.
74. Schmitz-Drager BJ, Goebell PJ, Ebert T, Fradet Y. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur Urol 2000;38:691-9, discussion 700.
75. Riley RD, Sauerbrei W, Altman DG. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer 2009;100:1219-29.
76. McShane LM, Altman DG, Sauerbrei W. Identification of clinically useful cancer prognostic factors: what are we missing? J Natl Cancer Inst 2005;97:1023-5.
77. Boyd MT, Vlatkovic N. p53: a molecular marker for the detection of cancer. Exp Opin Med Diagn 2008;2:1013-24.